# Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

> **NCT02992743** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 23 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** letetresgene autoleucel (GSK3377794)
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT02992743
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-06
- **Primary completion:** 2021-11-01
- **Final completion:** 2022-03-22
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02992743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02992743, "Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02992743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*